
CGON Stock Forecast & Price Target
CGON Analyst Ratings
Bulls say
CG Oncology is viewed favorably because cretostimogene has already shown strong clinical validation, including a 76% complete response rate in BOND-003 Cohort C and an 83% CR rate with Keytruda in CORE-001, while maintaining a clean safety profile with no Grade 3+ treatment-related adverse events. The company’s catalyst path is unusually clear, with PIVOT-006 topline data confirmed for November 2026, BLA completion in 4Q26, and additional durability updates expected in December 2026, any of which could expand creto’s role across intermediate-risk, high-risk BCG-unresponsive, and BCG-exposed NMIBC. Financially, CGON ended the quarter with $984.5M in cash, cash equivalents and marketable securities and a net loss of $56.9M, which supports operations through 2029 and gives it time to execute on a potentially broad commercial opportunity.
Bears say
CG Oncology is a developmental-stage biotech with extreme single-asset concentration, leaving valuation heavily dependent on cretostimogene’s clinical, regulatory, and commercial success in NMIBC. The key downside is that the company could face a CRL on its initial BLA in HRBCG-UR CIS NMIBC, disappointing data in IR/HR NMIBC, safety issues, or delays in its phase three and phase two programs, any of which could impair approval prospects and sales estimates. Competition, especially from TAR-200 and other current or future therapies, could limit market penetration and reimbursement, while weak commercial execution could force additional fundraising if operations cannot be funded from sales.
This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
CGON Analyst Forecast & Price Prediction
Start investing in CGON
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About CG oncology Inc (CGON) Forecast
CGON Analyst Forecast & Price Prediction
Start investing in CGON
Order type
Buy in
Order amount
Est. shares
0 shares